- Home
- CIA vs PLYX Comparison
CIA vs PLYX Comparison
Compare CIA & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIA | PLYX |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 262.3M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CIA | PLYX |
|---|---|---|
| Price | $4.58 | $7.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 144.5K | ★ 1.9M |
| Earning Date | 03-12-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $255,616,000.00 | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $28.23 | ★ N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $2.90 | $2.20 |
| 52 Week High | $6.40 | $8.15 |
Technical Indicators
Market Signals| Indicator | CIA | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 65.14 |
| Support Level | $4.53 | $2.37 |
| Resistance Level | $5.44 | N/A |
| Average True Range (ATR) | 0.31 | 1.43 |
| MACD | -0.02 | 0.26 |
| Stochastic Oscillator | 18.75 | 72.39 |
Price Performance
Historical ComparisonAbout CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.
About PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.